Detalhe da pesquisa
1.
No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial.
Clin Infect Dis
; 77(9): 1238-1246, 2023 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37335963
2.
Recombinant Adjuvanted Zoster Vaccine and Reduced Risk of Coronavirus Disease 2019 Diagnosis and Hospitalization in Older Adults.
J Infect Dis
; 225(11): 1915-1922, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34962997
3.
The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial.
J Infect
; 84(4): 490-498, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34963639
4.
Association Between Hemagglutination Inhibition Antibody Titers and Protection Against Reverse-Transcription Polymerase Chain Reaction-Confirmed Influenza Illness in Children 6-35 Months of Age: Statistical Evaluation of a Correlate of Protection.
Open Forum Infect Dis
; 9(2): ofab477, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35083365
5.
Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6-35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging Study.
Pediatr Infect Dis J
; 40(9): e333-e339, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34285165
6.
Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons: A Randomized Clinical Trial.
Pediatr Infect Dis J
; 39(1): e1-e10, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31725115
7.
Clinical Presentation of Influenza in Children 6 to 35 Months of Age: Findings From a Randomized Clinical Trial of Inactivated Quadrivalent Influenza Vaccine.
Pediatr Infect Dis J
; 38(8): 866-872, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31306399